Cargando…
Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models
Although botulinum neurotoxin serotype A (BoNT/A) products are common treatments for various disorders, there is only one commercial BoNT/B product, whose low potency, likely stemming from low affinity toward its human receptor synaptotagmin 2 (hSyt2), has limited its therapeutic usefulness. We expr...
Autores principales: | Elliott, Mark, Favre-Guilmard, Christine, Liu, Sai Man, Maignel, Jacquie, Masuyer, Geoffrey, Beard, Matthew, Boone, Christopher, Carré, Denis, Kalinichev, Mikhail, Lezmi, Stephane, Mir, Imran, Nicoleau, Camille, Palan, Shilpa, Perier, Cindy, Raban, Elsa, Zhang, Sicai, Dong, Min, Stenmark, Pål, Krupp, Johannes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357751/ https://www.ncbi.nlm.nih.gov/pubmed/30746458 http://dx.doi.org/10.1126/sciadv.aau7196 |
Ejemplares similares
-
Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems
por: Elliott, Mark, et al.
Publicado: (2017) -
The Expanding Therapeutic Utility of Botulinum Neurotoxins
por: Fonfria, Elena, et al.
Publicado: (2018) -
Recombinant botulinum neurotoxin serotype A1 in vivo characterization
por: Périer, Cindy, et al.
Publicado: (2021) -
The Isolated Mouse Jejunal Afferent Nerve Assay as a Tool to Assess the Effect of Botulinum Neurotoxins in Visceral Nociception
por: Retailleau, Kevin, et al.
Publicado: (2022) -
New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency
por: Burgin, David, et al.
Publicado: (2021)